Cyclacel Pharmaceuticals Announces Participation at the H.C. Wainwright 26th Annual Global Investment Conference
Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP), a biopharmaceutical company focused on developing innovative cancer medicines, has announced its participation in the H.C. Wainwright 26th Annual Global Investment Conference. The event will take place from September 9-11, 2024, both virtually and in-person at the Lotte New York Palace Hotel in New York City.
Spiro Rombotis, President & CEO of Cyclacel, will present an overview of the company's business during the conference. Institutional investors can register for the event through the provided link or access the presentation via Cyclacel's investor relations website. The virtual presentations will be available on-demand starting September 9 at 7:00 A.M. (ET).
Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP), un'azienda biofarmaceutica focalizzata nello sviluppo di farmaci innovativi per il cancro, ha annunciato la sua partecipazione al 26° Convegno Annuale Globale sugli Investimenti H.C. Wainwright. L'evento si svolgerà dal 9 all'11 settembre 2024, sia virtualmente che di persona presso il Lotte New York Palace Hotel a New York City.
Spiro Rombotis, Presidente e CEO di Cyclacel, presenterà una panoramica delle attività dell'azienda durante la conferenza. Gli investitori istituzionali possono registrarsi per l'evento attraverso il link fornito o accedere alla presentazione tramite il sito web delle relazioni con gli investitori di Cyclacel. Le presentazioni virtuali saranno disponibili on-demand a partire dal 9 settembre alle 7:00 A.M. (ET).
Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP), una empresa biofarmacéutica centrada en desarrollar medicamentos innovadores contra el cáncer, ha anunciado su participación en la 26.ª Conferencia Anual Global de Inversión H.C. Wainwright. El evento se llevará a cabo del 9 al 11 de septiembre de 2024, tanto de manera virtual como en persona en el Lotte New York Palace Hotel en la ciudad de Nueva York.
Spiro Rombotis, Presidente y CEO de Cyclacel, presentará una visión general del negocio de la empresa durante la conferencia. Los inversores institucionales pueden registrarse para el evento a través del enlace proporcionado o acceder a la presentación a través del sitio web de relaciones con inversores de Cyclacel. Las presentaciones virtuales estarán disponibles bajo demanda a partir del 9 de septiembre a las 7:00 A.M. (ET).
Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP), 혁신적인 암 치료제를 개발하는 데 집중하는 생명공학 회사가 H.C. Wainwright 제26회 연례 글로벌 투자 콘퍼런스에 참여할 것이라고 발표했습니다. 이 행사는 2024년 9월 9일부터 11일까지 뉴욕시의 Lotte New York Palace Hotel에서 대면 및 가상으로 진행됩니다.
Cyclacel의 회장 겸 CEO인 Spiro Rombotis가 콘퍼런스 중 회사 비즈니스 개요를 발표할 예정입니다. 기관 투자자는 제공된 링크를 통해 행사에 등록하거나 Cyclacel의 투자자 관계 웹사이트를 통해 발표에 접속할 수 있습니다. 가상 발표는 9월 9일 오전 7:00(ET)부터 주문형으로 제공됩니다.
Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP), une entreprise biopharmaceutique axée sur le développement de médicaments innovants contre le cancer, a annoncé sa participation à la 26e Conférence Annuelle Mondiale sur les Investissements H.C. Wainwright. L'événement se déroulera du 9 au 11 septembre 2024, à la fois virtuellement et en personne au Lotte New York Palace Hotel à New York.
Spiro Rombotis, Président et CEO de Cyclacel, présentera un aperçu des activités de l'entreprise lors de la conférence. Les investisseurs institutionnels peuvent s'inscrire à l'événement via le lien fourni ou accéder à la présentation sur le site Web des relations investisseurs de Cyclacel. Les présentations virtuelles seront disponibles à la demande à partir du 9 septembre à 7h00 (ET).
Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP), ein biopharmazeutisches Unternehmen, das sich auf die Entwicklung innovativer Krebsmedikamente konzentriert, hat seine Teilnahme an der 26. Jahresglobalen Investorenkonferenz von H.C. Wainwright bekannt gegeben. Die Veranstaltung findet vom 9. bis 11. September 2024 sowohl virtuell als auch persönlich im Lotte New York Palace Hotel in New York City statt.
Spiro Rombotis, Präsident und CEO von Cyclacel, wird während der Konferenz einen Überblick über das Unternehmengeben. Institutionelle Anleger können sich über den bereitgestellten Link zur Veranstaltung anmelden oder die Präsentation über die Investor-Relations-Website von Cyclacel abrufen. Die virtuellen Präsentationen sind ab dem 9. September um 7:00 Uhr (ET) auf Abruf verfügbar.
- None.
- None.
BERKELEY HEIGHTS, N.J., Sept. 04, 2024 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, today announced it will be featured as a presenting company at the H.C. Wainwright 26th Annual Global Investment Conference. The conference is being held on September 9-11, 2024. The in-person venue for the event is the Lotte New York Palace Hotel in New York City located at 455 Madison Avenue. Virtual participation will be staged simultaneously with over 550 company presentations scheduled as live feed or available on-demand.
Spiro Rombotis, President & CEO of the Company, will provide an overview of the Company's business during the presentation.
If you are an institutional investor, and would like to listen to the Company's presentation, please click on the following link (www.hcwevents.com/annualconference) to register for the conference. You can also access the presentation in the investor relations section of the Company’s website: www.cyclacel.com.
Event: HC Wainwright 26th Annual Global Investment Conference
Date: September 9-11, 2024
Location: Virtual to start on-demand on September 9 at 7:00 A.M. (ET) or in-person at the Lotte New York Palace Hotel, New York, NY.
About Cyclacel Pharmaceuticals, Inc.
Cyclacel is a clinical-stage, biopharmaceutical company developing innovative cancer medicines based on cell cycle, transcriptional regulation and mitosis biology. The transcriptional regulation program is evaluating fadraciclib, a CDK2/9 inhibitor, and the anti-mitotic program plogosertib, a PLK1 inhibitor, in patients with both solid tumors and hematological malignancies. Cyclacel's strategy is to build a diversified biopharmaceutical business based on a pipeline of novel drug candidates addressing oncology and hematology indications. For additional information, please visit www.cyclacel.com.
Forward-looking Statements
This news release contains certain forward-looking statements that involve risks and uncertainties that could cause actual results to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. Such forward-looking statements include, among other things, statements related to Cyclacel’s future plans and prospects, Cyclacel’s anticipated cash runway and the planned timing of data results and continued development of fadraciclib. Factors that may cause actual results to differ materially include market and other conditions, the risk that product candidates that appeared promising in early research and clinical trials do not demonstrate safety and/or efficacy in larger-scale or later clinical trials, trials may have difficulty enrolling, Cyclacel may not obtain approval to market its product candidates, the risks associated with reliance on outside financing to meet capital requirements, the risks associated with reliance on collaborative partners for further clinical trials, development and commercialization of product candidates and Cyclacel’s ability to regain and maintain compliance with Nasdaq’s continued listing requirements. You are urged to consider statements that include the words "may," "will," "would," "could," "should," "believes," "estimates," "projects," "potential," "expects," "plans," "anticipates," "intends," "continues," "forecast," "designed," "goal," or the negative of those words or other comparable words to be uncertain and forward-looking. For a further list and description of the risks and uncertainties the Company faces, please refer to our most recent Annual Report on Form 10-K and other periodic and other filings we file with the Securities and Exchange Commission and are available at www.sec.gov. Such forward-looking statements are current only as of the date they are made, and we assume no obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise.
Contact
| Company: | Paul McBarron, (908) 517-7330, IR@cyclacel.com |
© Copyright 2024 Cyclacel Pharmaceuticals, Inc. All Rights Reserved. The Cyclacel logo and Cyclacel® are trademarks of Cyclacel Pharmaceuticals, Inc.
FAQ
When is Cyclacel Pharmaceuticals (CYCC) presenting at the H.C. Wainwright Global Investment Conference?
Where is the in-person venue for the H.C. Wainwright conference featuring Cyclacel Pharmaceuticals (CYCC)?
Who will be presenting on behalf of Cyclacel Pharmaceuticals (CYCC) at the H.C. Wainwright conference?
How can investors access Cyclacel Pharmaceuticals' (CYCC) presentation at the H.C. Wainwright conference?
